Changes in electrophysiological findings of spinal muscular atrophy type I after the administration of nusinersen and onasemnogene abeparvovec: two case reports

Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy

(2021) Jerry R. Mendell et al.   JAMA Neurology

Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls

(2021) Basil T. Darras et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nerve conduction normal values for electrodiagnosis in pediatric patients

(2019) Conor S. Ryan et al.   MUSCLE & NERVE

Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases

(2018) Maite Calucho et al.   NEUROMUSCULAR DISORDERS

Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy

(2017) Richard S. Finkel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Spinal muscular atrophy: Diagnosis and management in a new therapeutic era

(2014) W. David Arnold et al.   MUSCLE & NERVE

Peripheral nerve abnormalities in pediatric patients with spinal muscular atrophy

(2012) Takahiro Yonekawa et al.   BRAIN & DEVELOPMENT

Spinal muscular atrophy

(2011) Adele D'Amico et al.   Orphanet Journal of Rare Diseases